Inovio Pharma (INO) Misses Q2 EPS by 5c

August 8, 2016 8:04 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Inovio Pharma (NASDAQ: INO) reported Q2 EPS of ($0.26), $0.05 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $6.2 million versus the consensus estimate of $4.95 million.

As of June 30, 2016, cash and cash equivalents and short-term investments were $134.5 million compared with $163.0 million as of December 31, 2015. There were 73.5 million shares outstanding and 81.2 million fully diluted.

The Company sold 119,400 shares of common stock at an average price of $11.12 per share, for net proceeds of $1.3 million, under the ATM common stock sales agreement implemented during the period.

For earnings history and earnings-related data on Inovio Pharma (INO) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings

Related Entities

Earnings

Add Your Comment